Search for: "Cephalon Inc."
Results 121 - 140
of 151
Sorted by Relevance
|
Sort by Date
9 Mar 2011, 3:00 am
Allergan, Inc (Chicago IP Litigation Blog) Synagis (Palivizumab) – US: PDL BioPharma settles Medimmune Synagis litigation for $93M (Patent Docs) TriCor (Fenofibrate) – US: Abbott and Elan end TriCor suit with Ranbaxy (Patent Docs) Valsartan – Norway: Oslo District Court holds Actavis’ Valsartan/HCTZ product infringes Novartis’ patent covering synthesis route for Valsartan; deals inter alia with scope of Valsartan SPC (The SPC Blog) [read post]
13 Jan 2010, 3:00 am
Cobrek Pharmaceuticals, Inc (Patent Docs) Nexium (Esomeprazole) – US: Teva drops patent challenge following settlement agreement with AstraZeneca over Nexium (IP Factor) (GenericsWeb) Nuvigil (Armodafinil) - US: Mylan confirms first-to-file patent challenge relating to sleep-disorder drug (SmartBrief) Nuvigil (Armodafinil) - US: Cephalon sues Watson for patent infringement following Para IV challenge (Patent Docs) (GenericsWeb) (Patentcircle) Tasigna (Nilotinib) - India:… [read post]
22 Mar 2011, 4:21 pm
: Board of Trustees of Leland Stanford Junior University v Roche Molecular Systems Inc (IPKat) US: That was unexpectedly… well… expected: BPAI affirms Examiner’s obviousness rejection in Ex Parte Akio Ochiai concerning a health food product containing curcumin, scymnol and isoflavones (BT-IP Notes) US: VirginiaTech VERSUS series – Drug evaluation DVDs available (FDA Law Blog) Products Diovan HCT (Valsartan, Hydrochlorothiazide) – Germany:… [read post]
27 Jul 2012, 12:40 pm
Cephalon, Inc., 2010 WL 1257790, at *6 (D.N.J. [read post]
9 Jan 2009, 3:00 am
You can separately subscribe to the IP Think Tank Global Week in Review at the Subscribe page: [duncanbucknell.com] Highlights this week included: Humira (Adalimumab) – US: Bayer HealthCare files patent infringement suit against Abbott Laboratories over Humira; Abbott fires back with lawsuit claiming Bayer’s patent invalid, not infringed or unenforceable (Law360) (Law360) (Philip Brooks' Patent Infringement Updates) (Patent Baristas) Sprycel (Dasatinib)… [read post]
5 Aug 2009, 5:35 am
(Spicy IP) Coversyl (Perindopril) – Canada: Court of Appeal upholds Trial Division finding of patent validity and infringement: Apotex v ADIR (Pharmacapsules@Gowlings) Cozaar (Losartan) – France: French Patent Office grants paediatric extension of French SPC for Losartan (The SPC Blog) Cozaar/Hyzaar (Losartan) – US: FDA prevails in generic Cozaar/Hyzaar 180-day exclusivity forfeiture litigation: Teva Pharmaceuticals v Sebelius (FDA Law Blog) Diflucan (Fluconazole)… [read post]
18 Jun 2019, 6:42 am
Aruba Networks, Inc., C.A. [read post]
12 Apr 2012, 10:56 am
Cephalon, 2009 WL 3245485, at *4 (D.N.J. [read post]
23 Sep 2015, 5:43 am
Cephalon, Inc., 2015 U.S. [read post]
22 Feb 2012, 10:21 am
Cephalon, Inc., 702 F. [read post]
3 Mar 2010, 5:05 am
(IP Think Tank) US: Reverse payments in generic drug settlements (Part II - Patent Docs) (Part III - Patent Docs) (Part IV - Patent Docs) US: Inability of patent examiner and Board to correctly read prior art reference necessitates intervention by Federal Circuit: In re Chapman (Holman's Biotech IP Blog) (Patent Docs) US: Patent infringement suit between NexMed and Beta Technologies stayed following determination that plaintiff NexMed may not own one of the patents-in-suit related to method of… [read post]
24 Feb 2010, 2:11 am
(IP Watch) Exploring a new angle in the TRIPS and drug patents debate (Spicy IP) EPO Enlarged Board of Appeal rules on patenting a method of treatment by surgery: G1/07 (IPKat) (EPLAW) (Patent Baristas) EPO Enlarged Board of Appeal decides on dosage regime – Swiss-type claims no longer available: G 2/08 – Dosage Regime/Abbot Respiratory (EPLAW) (Managing Intellectual Property) (IPKat) (Patent Baristas) India: Victory for access to medicines as Bayer loses lawsuit in India (GenericsWeb)… [read post]
6 Apr 2011, 12:18 am
427/09 Generics (UK) Ltd v Synaptech Inc (The SPC Blog) Simcor (Niacin, Simvastatin) – US: Abbott files patent infringement complaint against Watson following Para IV certification filing (Patent Docs) Thalomid (Thalidomide) – US: Decision in Lannett Thalomid bioequivalence study sample antitrust lawsuit could reignite debate on generic drug availability and REMS restrictions (FDA Law Blog) Yasmin (Drospirenone, Ethinylestradiol) – UK: Bayer Yasmin patents survive patent… [read post]
9 Apr 2009, 7:52 am
(IP Think Tank) Brazilian public-private partnerships in the pharma industry (IP tango) EU: ECJ to rule on reference on SPC Regulation interpretation from Lithuania in Kirin Amgen, Inc. v Lietuvos Respublikos valstybinis patentų biuras (The SPC Blog) India: Delhi High Court Dasatinib order: Is patent-drug regulatory linkage a necessity? [read post]
24 Feb 2010, 2:11 am
(IP Watch) Exploring a new angle in the TRIPS and drug patents debate (Spicy IP) EPO Enlarged Board of Appeal rules on patenting a method of treatment by surgery: G1/07 (IPKat) (EPLAW) (Patent Baristas) EPO Enlarged Board of Appeal decides on dosage regime – Swiss-type claims no longer available: G 2/08 – Dosage Regime/Abbot Respiratory (EPLAW) (Managing Intellectual Property) (IPKat) (Patent Baristas) India: Victory for access to medicines as Bayer loses lawsuit in India (GenericsWeb)… [read post]
3 Mar 2010, 5:05 am
(IP Think Tank) US: Reverse payments in generic drug settlements (Part II - Patent Docs) (Part III - Patent Docs) (Part IV - Patent Docs) US: Inability of patent examiner and Board to correctly read prior art reference necessitates intervention by Federal Circuit: In re Chapman (Holman's Biotech IP Blog) (Patent Docs) US: Patent infringement suit between NexMed and Beta Technologies stayed following determination that plaintiff NexMed may not own one of the patents-in-suit related to method of… [read post]
15 Jul 2009, 5:15 am
You can separately subscribe to the IP Think Tank Global Week in Review at the Subscribe page: [duncanbucknell.com] Highlights this week included: European Commission Competition DG releases final report on pharmaceutical sector (IPKat) (PatLit) (BLOG@IP::JUR) (IAM) (Managing Intellectual Property) (Intellectual Property Watch) (The SPC Blog) (IAM) US: Follow-on biologics proposals considered by US Senate HELP Committee; Committee passes amendment for 12-year biologics exclusivity period (FDA Law… [read post]
22 Feb 2008, 6:00 pm
Signature Financial Group, Inc., and AT&T Corp. v. [read post]
8 Dec 2015, 2:22 pm
AstraZeneca LP and Cephalon Inc. paid the United States $26.7 million and $4.3 million, respectively, in separate settlements for allegedly underpaying rebates owed under the Medicaid Drug Rebate Program. [read post]
2 Jun 2014, 4:43 am
Cephalon, Inc., No. 13-7167, 2014 U.S. [read post]
